Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Non-Current Assets (2023 - 2025)

Zenas BioPharma has reported Non-Current Assets over the past 3 years, most recently at $32.5 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $32.5 million for Q4 2025, up 131.18% from a year ago — trailing twelve months through Dec 2025 was $88.3 million (changed N/A YoY), and the annual figure for FY2025 was $32.5 million, up 131.18%.
  • Non-Current Assets for Q4 2025 was $32.5 million at Zenas BioPharma, up from $25.4 million in the prior quarter.
  • Over the last five years, Non-Current Assets for ZBIO hit a ceiling of $32.5 million in Q4 2025 and a floor of $8.4 million in Q4 2023.
  • Median Non-Current Assets over the past 3 years was $14.5 million (2025), compared with a mean of $17.2 million.
  • Biggest five-year swings in Non-Current Assets: surged 67.68% in 2024 and later soared 162.85% in 2025.
  • Zenas BioPharma's Non-Current Assets stood at $8.4 million in 2023, then surged by 67.68% to $14.0 million in 2024, then skyrocketed by 131.18% to $32.5 million in 2025.
  • The last three reported values for Non-Current Assets were $32.5 million (Q4 2025), $25.4 million (Q3 2025), and $14.5 million (Q2 2025) per Business Quant data.